Emergent BioSolutions Receives Major Contract for Anthrax Vaccine
Emergent BioSolutions Inc. has made a significant stride in its mission to safeguard public health with the recent announcement of a $30 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA). This agreement, aimed at supplying the CYFENDUS® vaccine, is a crucial move to enhance preparedness against the anthrax threat.
About CYFENDUS® Vaccine
CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) is specifically designed for post-exposure prophylaxis against anthrax. The vaccine is intended for adults aged between 18 and 65, particularly when combined with appropriate antibacterial drugs in the event of potential exposure to Bacillus anthracis, the bacteria responsible for anthrax.
Details of the Contract Modification
The modification announces that deliveries of the CYFENDUS® vaccine are set to commence shortly, with expectations for completion by March 2026. Paul Williams, senior vice president of Emergent, expressed pride in collaborating with the U.S. government to deliver essential medical countermeasures, underscoring the vaccine's role in national security and public safety.
Importance of Anthrax Preparedness
Anthrax remains classified as a Tier 1 biological threat due to its potential use in bioterrorism. With the alarming ability to jeopardize public health, ensuring the availability of effective vaccines is paramount. CYFENDUS® was granted approval by the U.S. Food and Drug Administration (FDA) in July 2023, marking a significant advancement in anthrax preparedness.
Continuing Support for U.S. Health Initiatives
This new contract highlights Emergent's commitment to maintaining a robust U.S.-based supply chain for its vaccines, essential for supporting national security priorities. The company has been at the forefront of developing solutions to protect against various health threats, including smallpox, Ebola, and now anthrax, affirming its mission to save lives.
Safety Information Regarding CYFENDUS®
Like any vaccine, CYFENDUS® carries safety considerations. It is contraindicated for individuals with a severe allergic reaction to a prior dose or any component of the vaccine. It is crucial for medical facilities administering the vaccine to be prepared to manage potential allergic reactions without delay.
Emergent BioSolutions’ Ongoing Commitment
Emergent BioSolutions has a long-standing dedication to developing life-saving solutions and addressing today’s health challenges. With over 25 years in the industry, the company stands ready to support the needs of the U.S. government and its health initiatives through its innovative vaccine solutions.
Frequently Asked Questions
What is CYFENDUS®?
CYFENDUS® is an anthrax vaccine approved for post-exposure prophylaxis to protect against potential exposure to anthrax bacteria.
How does the new contract impact Emergent BioSolutions?
The $30 million contract modification allows Emergent to deliver its CYFENDUS® vaccine to enhance national security and public health preparedness against anthrax threats.
What age group can receive CYFENDUS®?
CYFENDUS® is indicated for individuals aged between 18 and 65 years as part of a post-exposure prophylaxis strategy.
What are the safety precautions for CYFENDUS®?
CYFENDUS® should not be administered to individuals with a history of severe allergic reactions to previous doses or components of the vaccine.
How long until the vaccine is delivered?
Deliveries of CYFENDUS® are expected to begin soon, with the completion slated for March 2026.
